Special Issue

Biomaterial Modifications and Improvement of Their Biocompatibility 2.0

Message from the Guest Editors

Biomaterial is a substance that has been engineered to interact with biological systems for a medical purpose. Biomaterials may be natural or synthetic and are used in medical applications to support, enhance, or replace damaged tissue or a biological function. For years, biomaterials have been required to passively take over the function of a damaged tissue in the long term. However, the role that biomaterials play in the clinical treatment of damaged organs and tissues is changing, and biomaterials are currently expected to trigger and harness the self-regenerative potential of the body in situ. To this end, research is currently focused on changes in various aspects of biomaterials to improve their biocompatibility, i.e., the ability to perform with an appropriate host response. This Special Issue's Editors invite original contributions and review articles that address the modification of biomaterial aiming to enhance their biocompatibility in various fields of application. These include but are not limited to medical implants, healing and regeneration of human tissue, nanoparticles, and drug delivery systems.

Guest Editors

Prof. Dr. Viviana di Giacomo
Department of Pharmacy, University G. d'Annunzio, Chieti-Pescara, Italy
Prof. Dr. Agata Przekora-Kuśmierz
Independent Unit of Tissue Engineering and Regenerative Medicine, Medical University of Lublin, 20-093 Lublin, Poland

Deadline for manuscript submissions

closed (30 November 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/si/151296

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).